Phase 1B/2 study of PMX-60056 for the reversal of heparin anticoagulation

PolyMedix announced results from its Phase 1B/2 study of PMX-60056 designed to reverse the anticoagulant activity of both heparin and low molecule weight heparin (LMWH). In particular, PolyMedix reported clinical results demonstrating that, using measurements routinely available during cardiac surgery, clinicians can accurately predict a single reversing dose of PMX-60056 that will safely and effectively neutralize the anticoagulation effects of heparin. The study examined the dose-response, efficacy, and safety of PMX-60056 in reversing higher doses of heparin, including a dose routinely used in cardiac surgery, and also established that subsequent repeat anticoagulation with heparin was not inhibited by PMX-60056.

PMX-60056 is a synthetic, small-molecule heparin reversal-agent being developed to reverse the effects of both heparin and LMWH in a post-operative setting.  Currently, there is no FDA approved agent available to reverse the anticoagulant activity of LMWHs.

For more information call (484) 598-2340 or visit www.polymedix.com.